Somatic Cell Reprogramming to Retinal Cells via Small Molecules
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell replacement therapies for vision loss, particularly in retinal diseases, face limitations due to the use of stem cells, which raise ethical concerns, risk tumor growth, viral vector use, and host rejection, necessitating an alternative method to generate retinal replacement cells without stem cells.
Innovation Solution
The development of compositions and methods to reprogram somatic cells into therapeutic cells, such as retinal cells, using a combination of small molecules like valproic acid, CHIR99021, RepSox, and forskolin, along with enhancing agents, to convert somatic cells into chemically induced retinal cells (CiRCs) that demonstrate functional improvement in retinal degeneration models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If stem cell therapy is used for retinal cell replacement, then cell replacement capability is improved, but ethical concerns and tumor growth risk increase
Solution Approach 1:
The patent extracts and eliminates stem cells from the cell replacement approach, using instead directly reprogrammed somatic cells (fibroblasts converted to retinal cells) to avoid the ethical and tumorigenic issues associated with stem cells while maintaining the ability to replace retinal cells
Solution Approach 2:
The patent changes the cellular parameter from stem cell-based to somatic cell-based reprogramming, using small molecule compounds to induce direct conversion of fibroblasts into functional retinal cells, thereby altering the fundamental approach to cell generation
2Productivity
If stem cell therapy is used for retinal cell replacement, then cell replacement capability is improved, but concern for viral vector use increases
Solution Approach 1:
The patent removes viral vectors from the methodology by using chemical small molecules to induce direct reprogramming of somatic cells, eliminating the need for viral-based gene delivery systems that raise safety and ethical concerns
3Productivity
If stem cell therapy is used for retinal cell replacement, then cell replacement capability is improved, but host rejection risk increases
Solution Approach 1:
The patent employs patient-specific somatic cells that are reprogrammed to replace retinal cells, creating autologous cells that are genetically matched to the patient and thus unlikely to be rejected by the host immune system
4Object-affected harmful factors
If somatic cell reprogramming is used, then ethical concerns and tumor growth risk are reduced, but manufacturing complexity increases
Solution Approach 1:
The patent simplifies the reprogramming process by using a defined cocktail of small molecule compounds that can be easily administered to somatic cells, avoiding the complexity of stem cell differentiation protocols while achieving direct conversion to functional retinal cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the generation of therapeutic cells with characteristics suitable for treating vision loss by converting somatic cells into functional retinal cells, such as photoreceptor precursor-like cells, retinal pigment epithelial cells, and retinal ganglion cells, showing improved retinal function in mouse models and potential for clinical application.
Implementation Method 1
five small molecules (5C) that can chemically induce conversion to other target cell types
Data Source
AI summary
Certain aspects of the current invention are directed to a reprogramming of somatic cells to provide therapeutic cells for treatment of diseases such as retinopathies. Certain aspects of the invention are directed to reprogramming compositions, as well as the use of such compositions, for reprogramming somatic cells, the compositions including five small molecules (5C) that can chemically induce conversion to other target cell types.